Co-Amorphous Ursolic Acid-Quercetin Complex Improves Solubility and In Vivo Expectorant-Antitussive Activity. [PDF]
Jiang Y, Qiu Z, Lin B, Yang Z, Hong Y.
europepmc +1 more source
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung +15 more
wiley +1 more source
Illuminating the black box: Mapping the fates of polymeric micelle drug carriers <i>in vivo</i>. [PDF]
Ding X.
europepmc +1 more source
Intelligent Programmable Membrane Nanosponge for Early Virus Blocking
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen +17 more
wiley +1 more source
Investigation of In Vitro α-Amylase Inhibitory, Antioxidant, Phytochemical Profiling, Molecular Docking, and Swiss ADME Analysis of Magnolia zotictla. [PDF]
Zahoor M +5 more
europepmc +1 more source
Hydrodynamically decoupled nanoprecipitation (HDNP): A multi-stage strategy for supersaturation, controlled delayed nucleation, and stabilization of low LogP poorly-water soluble drugs. [PDF]
Castillo-Henríquez L +7 more
europepmc +1 more source
Nanocrystals for the Parenteral Delivery of Poorly Water-Soluble Drugs [PDF]
Nanocrystals have drawn increasing interest in pharmaceutical industry because of the ability to improve dissolution of poorly water-soluble drugs. Nanocrystals can be produced by top-down and bottom-up technologies and have been explored for a variety of therapeutic applications.
Bo Sun, Yoon Yeo
exaly +3 more sources
Solubilization Techniques Used for Poorly Water-Soluble Drugs
About 40% of approved drugs and nearly 90% of drug candidates are poorly water-soluble drugs. Low solubility reduces the drugability. Effectively improving the solubility and bioavailability of poorly water-soluble drugs is a critical issue that needs to be urgently addressed in drug development and application.
Wei He
exaly +3 more sources

